Many scientific careers follow unexpected paths. Mine has taken me from biomaterials and microfluidics to biomedical implants and, eventually, to nanofiber-based purification technologies for biologics manufacturing.

Along the way, I’ve been fascinated by how advances in materials science can unlock new possibilities in medicine. Whether that’s engineering biodegradable heart valves or developing nanofiber platforms capable of accelerating viral vector purification, each step has reinforced one lesson: innovation often happens where disciplines intersect.

For many children, fireworks are simply about the thrill of lighting them and watching colors explode across the night sky. For me, the fascination was different. I wanted to understand why those colors appeared in the first place.

At the age of seven, curiosity got the better of me. On a warm summer day, I gathered as many fireworks as I could find, carefully removed the ignition and fuse components, wrapped the powder in foil, and tried to light it. Much to my surprise, nothing happened. While the experiment itself was a failure, it did teach me something valuable: never use foil.

The fireworks may not have ignited, but that moment sparked something else. A lasting curiosity about how science works beneath the surface.

That curiosity stayed with me throughout my education. It was during my first master’s degree in biomaterials and tissue engineering that I began to see how scientific discovery could translate into real-world impact. I became increasingly interested in how biology, chemistry, engineering, and physics could be brought together to tackle some of the most challenging problems in modern medicine.

Before committing to a PhD, I wanted to explore that intersection further. I went on to complete a second master’s degree in microfluidics, where I worked on creating microbubbles (<10 µm) from biocompatible polymers. These could be used as ultrasound contrast agents for medical imaging or even transformed into edible foams designed as low-calorie food for diabetic patients. It was another reminder of how versatile science can be when different fields converge.

This curiosity-driven journey eventually led me to pursue a PhD at University College London (UCL), where I focused on electrospinning and discovered an entirely new nano-scale world of electrospun nanofibers. These incredibly fine materials opened up exciting possibilities for biomedical engineering.

During my postdoctoral research, I had the opportunity to apply this knowledge in a European FP7 project focused on developing a biodegradable heart valve for infants with congenital heart defects. Working alongside surgeons and industrial partners from five different countries, our goal was to engineer a solution that could grow with the patient, potentially reducing the need for repeated surgeries.

Looking back, this remains one of the most rewarding projects I have worked on. Waking up each morning knowing that the work we were doing might one day help save a child’s life was a powerful motivation.

After a short period as a teaching fellow, I realized that my true calling was research. Soon after, a small company called Puridify approached me. They were interested in my experience with electrospun nanofibers, but this time for a completely different application: protein purification.

It was yet another demonstration of the versatility of nanofiber technology.

Puridify’s nanofiber platform was eventually acquired by Cytiva, where I had the opportunity to collaborate with talented scientists from around the world and see the technology evolve within a global bioprocessing environment.

I joined Astrea Bioseparations in November 2022, where I began working with the company’s proprietary AstreAdept® nanofiber-based membranes. One of the key platforms built around this technology is the LentiHERO® device family, designed to enable rapid purification of lentiviral vectors across a wide range of scales, from 10 mL to 10 L loading volumes.

While biologics purification is not new to the industry, the use of nanofiber membranes offers a step-change in processing efficiency, particularly as manufacturing scales and costs increase.

Lentiviral vectors present unique purification challenges. Many current approaches rely on legacy technologies that were not originally designed for these complex biologics, which can lead to slower processing times and inefficiencies during scale-up.

This is where AstreAdept® stands out.

The nanofiber structure enables rapid mass transfer and efficient capture, allowing for faster purification while maintaining high recovery. When integrated into the Nereus LentiHERO® device, it creates a streamlined, fit-for-purpose platform that can significantly accelerate lentivirus purification workflows.

For those of us working closely with this technology, the potential impact is clear. Faster processing, reduced buffer consumption, and improved operational efficiency not only simplify downstream processing, but also support more sustainable and cost-effective manufacturing.

As cell and gene therapies continue to evolve, innovations like AstreAdept® and LentiHERO® are helping move the field toward practical, scalable solutions for producing the lentiviral vectors that power the next generation of life-changing treatments.